Teduglutide (Gattex/Revestive): Complete Research Profile — FDA-Approved GLP-2 Analog for Short Bowel Syndrome and Intestinal Adaptation Research (2026)

# Teduglutide (Gattex/Revestive): Complete Research Profile — FDA-Approved GLP-2 Analog for Short Bowel Syndrome and Intestinal Adaptation Research (2026)

> Research Use Only (RUO). This article discusses teduglutide as both an FDA-approved therapeutic (Gattex/Revestive) and as a research reagent. The research context sections below are intended for scientists studying GLP-2 receptor pharmacology and intestinal biology in controlled laboratory settings. Nothing in this profile constitutes medical advice, dosing guidance for human therapeutic use, or endorsement of off-label administration. Researchers must follow all applicable institutional and regulatory requirements.

Teduglutide — marketed as Gattex in the United States and Revestive in Europe — is a synthetic, recombinant analog of glucagon-like peptide-2 (GLP-2) and the first GLP-2 receptor agonist approved for clinical use. Developed to overcome the pharmacokinetic limitations of native GLP-2 (which is degraded within minutes), teduglutide carries a single amino acid substitution that confers resistance to enzymatic cleavage and enables once-daily dosing. Its FDA approval on December 21, 2012, for adult short bowel syndrome (SBS) patients dependent on parenteral nutrition, followed by a pediatric expansion, represents a milestone in gut-hormone pharmacology. Beyond clinical use, teduglutide is extensively deployed as a research tool for probing GLP-2R signaling, intestinal adaptation, and mucosal biology.

For dosing, reconstitution, and protocol details, see our GLP-2 Dosage Protocol Guide: Gut Repair Research (2026).

For the parent hormone and the proglucagon family, see the Peptides.SO GLP-2 intestinotrophic hormone profile. For GLP-1 class context, see the exenatide research profile and liraglutide research profile.

---

Background: What Is Teduglutide?

GLP-2 is a 33-amino acid peptide secreted by intestinal L-cells in response to luminal nutrients. It acts through the GLP-2 receptor (GLP-2R), a class B G-protein-coupled receptor, to promote intestinal mucosal growth, barrier integrity, and blood flow. While physiologically critical, native GLP-2 has a plasma half-life of approximately 7 minutes due to rapid N-terminal cleavage by dipeptidyl peptidase-4 (DPP-4) — making it unsuitable as a therapeutic or as a stable research reagent.

Teduglutide addresses this limitation with a single-point substitution: alanine at position 2 is replaced by glycine (Ala2→Gly2). This modification, sometimes written as [Gly2]-GLP-2, sterically blocks DPP-4 access to the N-terminal cleavage site while preserving full GLP-2R agonist activity. The result is a peptide that is 100% intact following 24-hour incubation with purified DPP-4, dramatically extending bioavailability and enabling rational clinical dosing.

Teduglutide is manufactured using recombinant DNA technology in Escherichia coli. Its molecular weight is 3,752 Daltons and its amino acid sequence is identical to human GLP-2 at all 32 positions except position 2.

---

Mechanism of Action

GLP-2 Receptor Agonism

Teduglutide selectively activates GLP-2R, a class B (secretin-family) GPCR expressed primarily in:

• •Intestinal subepithelial myofibroblasts
• •Enteric neurons
• •Enteroendocrine cells

Receptor activation couples to Gs/adenylyl cyclase/cAMP signaling, triggering release of downstream mediators — including insulin-like growth factor-1 (IGF-1), keratinocyte growth factor (KGF/FGF-7), and epidermal growth factor (EGF) — that act on intestinal epithelial cells to promote proliferation and suppress apoptosis.

Intestinotrophic Effects

The primary tissue-level consequences of GLP-2R activation by teduglutide include:

• •Increased villus height — expansion of the absorptive surface per unit length of gut
• •Increased crypt depth — reflecting enhanced crypt cell proliferation
• •Reduced epithelial apoptosis — net gain in mucosal cell mass
• •Enhanced intestinal blood flow — GLP-2 acutely increases superior mesenteric artery flow, measured by Doppler ultrasound in human studies (Physiol Rep, 2025)
• •Reduced gastric emptying and secretion — slowing transit to extend nutrient contact time
• •Upregulation of nutrient transporters — enhanced expression of digestive enzymes and transport proteins in the intestinal epithelium

These combined effects increase the functional absorptive capacity of the remaining gut — the central goal in short bowel syndrome therapy.

Indirect Epithelial Action

An important mechanistic nuance: GLP-2R is not expressed by intestinal enterocytes themselves. Epithelial effects of teduglutide are mediated indirectly through GLP-2R-expressing myofibroblasts and enteric neurons that release paracrine growth factors. This has implications for research design — experiments measuring teduglutide effects on isolated enterocytes may miss the cell-non-autonomous signaling mode that operates in intact tissue.

---

Comparison to Native GLP-2: The DPP-4 Resistance Advantage

The pharmacokinetic data above come from clinical pharmacology studies submitted as part of the Gattex NDA. The shorter half-life in SBS patients relative to healthy subjects reflects altered absorption and clearance dynamics in bowel-compromised individuals.

This single-residue modification — the Ala2→Gly2 substitution — exemplifies the rational engineering principle underlying the entire incretin-analog field: minimal structural change to defeat the key degradation pathway while preserving receptor recognition. The same logic was applied to create liraglutide, semaglutide, and other DPP-4- or protease-resistant analogs from their respective endogenous hormones.

---

Research Applications

Short Bowel Syndrome (SBS) and Intestinal Rehabilitation

SBS results from loss of functional intestinal mass — through resection, congenital defect, or disease — leaving patients with inadequate absorptive capacity and dependence on parenteral nutrition (PN). Teduglutide's approved indication directly addresses this: by driving mucosal growth and enhancing absorptive function, it enables reduction or elimination of PN dependence.

Phase III evidence demonstrated significant reductions in required PN/IV infusion volume from baseline, with a proportion of patients achieving PN independence in pivotal trials. Key published research includes:

• •Structural adaptation confirmed by histology: A multicenter, randomized, placebo-controlled trial (PMID: 23426461) in 83 PN-dependent SBS patients showed teduglutide enhanced small-intestinal mucosal architecture at 24 weeks without dysplastic changes — validating the histomorphometric readout in human tissue.

• •Parenteral nutrition reduction: A real-world effectiveness study (PMID: 24134154) documented progressive PN volume reduction in PN-dependent adult SBS subjects, with effects emerging over months of continuous treatment.

• •Morphological adaptation documented by capsule endoscopy: A case report (PMID: 32187383) in a patient with SBS-IF due to Crohn's disease demonstrated marked villous hypertrophy confirmed by endoscopic capsule and histology after 12 months of teduglutide — the first publication directly demonstrating morphological intestinal adaptation in a human treated with a GLP-2 analog.

For research models, SBS is routinely induced by surgical small bowel resection in rodents. Teduglutide administration in such models drives measurable increases in remnant bowel mass, crypt-villus morphometry, and nutrient absorption — providing quantitative endpoints for preclinical efficacy testing of novel intestinal therapies.

Crohn's Disease with Intestinal Failure

SBS frequently co-occurs with Crohn's disease (CD), the underlying cause of many bowel resections. A 2024 retrospective case series published in Crohn's & Colitis 360 (Siu et al., 2024) found that teduglutide reduced parenteral support requirements, antidiarrheal medication use, and stool output in SBS patients with concurrent CD — without significant interference with immunosuppressive therapy. This positions teduglutide as a research tool for studying mucosal healing in inflammatory bowel disease contexts, not just resection-based malabsorption.

An open question in the field is whether intestinal adaptation achieved with teduglutide is sustained after discontinuation or requires lifelong treatment. A 2021 review (PMID: 34399400) found no consensus — some patients maintained adaptation after stopping therapy, others relapsed. This creates ongoing research interest in the biology of adaptation permanence.

Pediatric SBS — Expanding Research Population

FDA approval was expanded to include pediatric patients 1 year of age and older following controlled trials in children. A 2024 long-term extension analysis published in the Journal of Pediatric Gastroenterology and Nutrition (Wales et al., 2024) reported on 96-week safety and efficacy in pediatric SBS-IF, finding that long-term teduglutide was associated with improved response including PN weaning in a subset of patients. Children may have greater natural adaptation capacity, making the interaction between teduglutide-driven adaptation and growth-dependent recovery an active area of investigation.

Inflammatory and Barrier Research

Beyond SBS, teduglutide is studied in models of:

• •Chemotherapy-induced mucositis — GLP-2R agonism protects the intestinal mucosa against cytotoxic injury, and teduglutide is investigated as a potential radioprotective/chemoprotective tool
• •Gastrointestinal inflammation — GLP-2R activation can mitigate gut inflammation in preclinical models (Nat Commun, 2026)
• •Intestinal permeability models — tight-junction integrity, bacterial translocation, and barrier-function assays using teduglutide as the GLP-2R-activating probe

Neuro-Metabolic and Systemic Research

Recent research extends teduglutide beyond gut biology. Studies of GLP-2/GIP dual receptor agonists in neurodegeneration models (Peptides, 2026) and mapping of global GLP-2R activation effects on systemic metabolism (Metabolism, 2026) position teduglutide within a broader gut-brain-liver axis research program.

---

Dosing in Published Literature

In the approved clinical indication (SBS), teduglutide is administered at 0.05 mg/kg of body weight per day as a subcutaneous injection. This dose was established through Phase I pharmacokinetic and dose-ranging studies and validated in Phase III randomized controlled trials.

In research contexts:

• •Rodent models: Typical preclinical doses range from 25–100 µg/kg/day subcutaneously, administered once daily; morphometric endpoints (villus height, crypt depth, bowel weight) are assessed at 4–8 weeks post-resection
• •In vitro receptor binding assays: Concentration ranges of 1 nM–1 µM are commonly used for cAMP accumulation and receptor saturation studies
• •Physiological comparisons: Co-administration of native GLP-2 vs. teduglutide at equimolar doses is used to demonstrate the half-life advantage in ex vivo tissue assays

The dose of 0.05 mg/kg/day in clinical use translates to approximately 3.5 mg/day for a 70 kg adult. Research publications frequently report dose in mg/kg or µg/kg — always confirm units when comparing across studies.

---

Storage and Reconstitution

Commercial formulation (Gattex/Revestive):

• •Each vial contains 5 mg of teduglutide as a white lyophilized powder
• •Reconstitution: Add 0.5 mL of Sterile Water for Injection (provided in a prefilled syringe) to yield a 10 mg/mL solution
• •The reconstituted solution should be clear and colorless; discard if particulate matter or discoloration is observed
• •No preservatives — administer immediately after reconstitution or within 3 hours if stored at room temperature (do not refrigerate reconstituted solution)
• •Lyophilized powder: refrigerate at 2°C–8°C; do not freeze; protect from light

Research-grade reagent handling:

• •Store lyophilized peptide at −20°C; after opening, aliquot to avoid repeated freeze-thaw cycles
• •Reconstitute in sterile water or PBS at neutral pH; teduglutide is soluble at neutral-to-alkaline pH (the Gly2 substitution does not alter solubility relative to native GLP-2)
• •Confirm identity by mass spectrometry (expected MW 3,752 Da) and purity by HPLC (≥95% purity for research use)
• •The Gly2 substitution confers DPP-4 resistance but the peptide remains subject to other serine proteases — use general protease inhibitor cocktails in plasma-containing assay buffers
• •For in vitro assay stability, add protease inhibitors and maintain cold-chain handling

For general peptide reconstitution guidance, see the Peptides.SO peptide reconstitution guide. For evaluating research-grade supplier documentation, see how to read a certificate of analysis.

---

Research Supplier Availability and Pricing

Teduglutide is available from several research-grade peptide suppliers at significantly lower price points than the brand-name clinical formulation. As an FDA-approved compound with a known sequence (33 residues, Gly2 substitution), it is routinely synthesized by peptide chemistry vendors.

Representative research pricing (2026, Research Use Only):

• •Nationwide Peptides: GLP-2T (Teduglutide) listed at approximately $38–$61 for standard research quantities
• •Selleck Chemicals / AbMole: Teduglutide (ALX-0600; CAS 197922-42-2) available as a GLP-2 analogue research reagent; confirm lot-specific purity and mass spec data before use
• •Biosynth / Research suppliers: Available under CAS 197922-42-2; request CoA confirming sequence identity and ≥95% HPLC purity

Important sourcing notes:

• •Verify the Gly2 substitution is confirmed by mass spec in the supplied CoA — some vendors may supply native GLP-2 (Ala2) under similar catalog names
• •Research-grade teduglutide is offered strictly for laboratory use; it is not pharmaceutical-grade Gattex
• •Price varies substantially by purity specification, vial size, and vendor; compare Peptides.SO supplier comparison tools for current market pricing

For evaluating supplier quality and documentation standards, see how to choose a research peptide supplier.

---

Positioning Within the GLP Peptide Family

Teduglutide occupies a unique niche within the proglucagon-derived peptide family: it is the only GLP-2R-selective agonist to reach clinical approval, while GLP-1 receptor agonists (semaglutide, liraglutide, exenatide, tirzepatide) have dominated metabolic disease research.

The next generation of GLP-2 analogs — including apraglutide (t½ ~72h in healthy subjects, enabled by 4 amino acid substitutions) — are benchmarked against teduglutide in intestinal microbiota and morphology studies (Clin Nutr ESPEN, 2026; Bioconjug Chem, 2026). For researchers, teduglutide remains the reference standard GLP-2R agonist against which new analogs are compared.

For broader GLP class context:

• •GLP-2 (intestinotrophic hormone) — the parent peptide and primary reference for receptor biology
• •Exenatide (Byetta/Bydureon) — first FDA-approved GLP-1 receptor agonist; structural and mechanistic parallels
• •Liraglutide (Victoza/Saxenda) — DPP-4-resistant GLP-1 analog; same protease-evasion strategy applied to GLP-1
• •GLP-1 receptor agonists overview — class-level comparison including mechanism and indications

---

Frequently Asked Research Questions

Is teduglutide FDA-approved?

Yes. Teduglutide (Gattex) received FDA approval on December 21, 2012, for adult SBS patients dependent on parenteral support. The approved indication was later extended to pediatric patients 1 year of age and older.

How does teduglutide differ from native GLP-2?

By a single substitution — glycine for alanine at position 2 — which fully blocks DPP-4 cleavage. This extends plasma half-life from ~7 minutes to ~2 hours, enabling once-daily subcutaneous dosing vs. continuous infusion required for native GLP-2. GLP-2R agonist activity is fully preserved (Compr Physiol, 2026).

What are the primary research readouts for teduglutide studies?

Intestinal morphometry (villus height, crypt depth, bowel weight), mucosal blood flow (Doppler), nutrient transporter expression, PN volume reduction in SBS models, epithelial proliferation (BrdU/Ki67), and apoptosis rates. In cell-based assays: cAMP accumulation at GLP-2R (PMID: 23426461).

What controls are appropriate for teduglutide experiments?

Include: (1) Glp2r-knockout animals to confirm receptor-mediated effects, (2) native GLP-2 at equimolar dose to demonstrate the half-life advantage, (3) GLP-2R antagonist (e.g., GLP-2(3-33)) to confirm on-target activity, and (4) vehicle-only controls. For in vitro work, verify GLP-2R expression in your cell system — many intestinal cell lines lack endogenous GLP-2R.

Is teduglutide being studied beyond SBS?

Yes. Active research areas include: chemotherapy-induced mucositis, IBD mucosal healing, Crohn's disease with intestinal failure (Siu et al., 2024), intestinal permeability, neuro-metabolic crosstalk, and GLP-2/GIP dual agonist development.

How does teduglutide compare to apraglutide?

Teduglutide is a first-generation DPP-4-resistant analog (t½ ~2h, once-daily dosing). Apraglutide carries 4 amino acid substitutions enabling a ~72-hour half-life in healthy subjects, enabling weekly dosing in clinical studies — a next-generation improvement on the same intestinotrophic axis.

---

Summary

Teduglutide (Gattex/Revestive) is the landmark FDA-approved GLP-2 receptor agonist — a Gly2-substituted, DPP-4-resistant analog of native GLP-2 that drives intestinal mucosal growth, blood flow, and absorptive capacity through GLP-2R/Gs/cAMP signaling. Its single amino acid substitution (Ala2→Gly2) extends plasma half-life ~17-fold over native GLP-2, enabling once-daily subcutaneous dosing at 0.05 mg/kg/day. In clinical use, teduglutide reduces parenteral nutrition dependence in adult and pediatric SBS patients; in research settings, it serves as the reference standard GLP-2R agonist for probing intestinal adaptation, mucosal biology, and gut-hormone pharmacology. As with all compounds profiled on Peptides.SO, research-grade teduglutide is presented for Research Use Only — not for human or veterinary therapeutic use outside appropriate clinical or regulatory frameworks.

---

This article is provided for informational and educational purposes. Research-grade teduglutide is intended for laboratory use only. Gattex/Revestive is an FDA-approved pharmaceutical; any therapeutic use must be under the supervision of licensed medical professionals. Always comply with institutional and regulatory requirements for research with peptide reagents.